Cefpodoxime Proxetil

Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases[1][2][3][4][5].

Product Specifications

CAS Number

[87239-81-4]

Product Name Alternative

U-76,252; CS-807

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial; Penicillin-binding protein (PBP)

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/cefpodoxime-proxetil.html

Purity

98.93

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C(N12)=C(COC)CS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OC)=O)C1=O)OC(OC(OC(C)C)=O)C

Molecular Formula

C21H27N5O9S2

Molecular Weight

557.60

Precautions

H302, H315, H319, H335

References & Citations

[1]Todd W. M. (1994) . Cefpodoxime proxetil: a comprehensive review. International journal of antimicrobial agents, 4 (1), 37–62. |[2]Date, A. A., & Nagarsenker, M. S. (2007) . Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. International journal of pharmaceutics, 329 (1-2), 166–172.|[3]Borin M. T. (1991) . A review of the pharmacokinetics of cefpodoxime proxetil. Drugs, 42 Suppl 3, 13–21. |[4]Frampton, J. E., et al., (1992) . Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs, 44 (5), 889–917. |[5]Pahwa R, Rana A S, Dhimans S, et al. Cefpodoxime proxetil: an update on analytical, clinical and pharmacological aspects [J]. J Curr Chem Pharm Sc, 2015, 5 (2) : 56-66.|[6]Utsui, Y., et al., (1987) . In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrobial agents and chemotherapy, 31 (7), 1085–1092.